Search results
Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Yahoo Finance· 3 hours agoCEO Bob Bradway shared a peek at phase II results of the potential competitor to market leaders...
Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 hours agoNovo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript May 2, 2024 Novo Nordisk A/S misses on...
Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
Reuters via Yahoo News· 13 hours agoNovo Nordisk were last down 4.4% by 1022 GMT, having hit their lowest in two months earlier in the...
Wegovy maker Novo Nordisk down 4%, heads for worst day since October
CNBC· 11 hours agoShares of Danish pharmaceutical giant Novo Nordisk slid 4% on Friday, extending a 2.7% loss on...
How the CFOs of Eli Lilly and Novo Nordisk are coping with ‘unprecedented demand’ for weight-loss...
Fortune via AOL· 13 hours agoGood morning. At least one sector has shrugged off the current economic uncertainty, and now the...
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
Zacks via Yahoo Finance· 1 day agoNovo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and...
Novo Nordisk, Eli Lilly drop on Amgen competition concerns By Investing.com
Investing.com· 12 hours agoShares of Novo Nordisk (NYSE:NVO) and Eli Lilly & Co. (NYSE:LLY) are down premarket Friday as competition in the GLP-1 market. Amgen (NASDAQ:AMGN) disclosed ...
Novo Nordisk To Slash Prices On Buzzy Drugs Ozempic and Wegovy
Futurism via Yahoo Finance· 8 hours agoNovo Nordisk, the Danish maker of the injectable diabetes drug Ozempic and its sister weight-loss...
Amgen Knocks Novo Nordisk's Ozempic Stock Rally. Its Stock Is Flying.
The Wall Street Journal· 9 hours agoAmgen’s progress on its experimental weight-loss drug offered investors a reminder that Novo Nordisk...
This Is a Huge Sigh of Relief for Novo Nordisk Investors
Motley Fool via Yahoo Finance· 13 hours agoNovo Nordisk's (NYSE: NVO) success hinges on two key products: Ozempic and Wegovy. The former is a...